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___________________________________________________________________________ 
Abstract 
In previous studies we had administered benzo[a]pyrene (BaP) to genetically engineered mice 
(HRN) which do not express NADPH:cytochrome P450 oxidoreductase (POR) in hepatocytes 
and observed higher DNA adduct levels in livers of these mice than in wild-type mice. To 
elucidate the reason for this unexpected finding we have used two different settings for in 
vitro incubations; hepatic microsomes from control and BaP-pretreated HRN mice and 
reconstituted systems with cytochrome P450 1A1 (CYP1A1), POR, cytochrome b5, and 
epoxide hydrolase (mEH) in different ratios. In microsomes from BaP-pretreated mice, in 
which Cyp1a1 was induced, higher levels of BaP metabolites were formed, mainly of BaP-
7,8-dihydrodiol. At a low POR:CYP1A1 ratio of 0.05:1 in the reconstituted system, the 
amounts of BaP diones and BaP-9-ol formed were essentially the same as at an equimolar 
ratio, but formation of BaP-3-ol was ~1.6-fold higher. Only after addition of mEH were BaP 
dihydrodiols found. Two BaP-DNA adducts were formed in the presence of mEH, but only 
one when CYP1A1 and POR were present alone. At a ratio of POR:CYP1A1 of 0.05:1, 
addition of cytochrome b5 increased CYP1A1-mediated BaP oxidation to most of its 
metabolites indicating that cytochrome b5 participates in the electron transfer from NADPH to 
CYP1A1 required for enzyme activity of this CYP. BaP-9-ol was formed even by CYP1A1 
reconstituted with cytochrome b5 without POR. Our results suggest that in livers of HRN 
mice Cyp1a1, cytochrome b5 and mEH can effectively activate BaP to DNA binding species, 
even in the presence of very low amounts of Por. 
___________________________________________________________________________  
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1. Introduction 
Benzo[a]pyrene (BaP) is a polycyclic aromatic hydrocarbon (PAH) that has been 
classified as human carcinogen (Group 1) by the International Agency for Research on Cancer 
(IARC, 2010). BaP and other PAHs are produced mainly by incomplete combustion of 
organic matter and are ubiquitous in the environment, leading to measurable levels of 
exposure in the general population (IARC, 2010). Beside the inhalation of polluted air, the 
main sources of exposure are tobacco smoke and the diet (Kim et al., 2011; Labib et al., 2012; 
Phillips and Venitt, 2012; Sidden et al., 2012). Chronic exposure of laboratory animals to BaP 
has been associated with the development of cancer, primarily skin, stomach and lung (IARC, 
2010). 
BaP requires metabolic activation prior to reaction with DNA (Baird et al., 2005). 
Cytochrome P450 (CYP) enzymes, mainly CYP1A1 and 1B1, are the most important 
enzymes in this process (Baird et al., 2005; Hamouchene et al., 2011), in combination with 
microsomal epoxide hydrolase (mEH). First, CYP1A1 or 1B1 enzymes oxidize BaP to an 
epoxide that is then converted to a dihydrodiol by mEH (i.e. BaP-7,8-dihydrodiol); then 
further bioactivation by CYP1A1 or 1B1 leads to the ultimately reactive species BaP-7,8-
dihydrodiol-9,10-epoxide (BPDE) that can react with DNA, forming adducts preferentially at 
guanine residues. The 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-
tetrahydrobenzo[a]pyrene (dG-N2-BPDE) adduct is the major product of BPDE with DNA in 
vitro and in vivo (Phillips, 2005). BaP is, however, oxidized also to other metabolites such as 
the other dihydrodiols, BaP-diones and hydroxylated metabolites (Bauer et al., 1995; Chun et 
al., 1996; Kim et al., 1998; Jiang et al., 2007; Zhu et al., 2008).  Among them, 3-hydroxy-BaP 
(BaP-3-ol), formed by CYP1A1, is considered the major detoxification product of BaP 
oxidation, because it is known to inhibit mutagenesis and tumorigenesis (Huang et al., 1986). 
In mouse hepatoma Hepa1c1c7 cells, which express inducible CYP1A1, this metabolite was 
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the major metabolite formed after exposure to BaP (Holme et al., 2007).  Even though this 
CYP1A1-mediated BaP oxidation product as well as most of the other BaP metabolites are 
detoxification products, 9-hydroxy-BaP (BaP-9-ol) is a precursor of 9-hydroxy-BaP-4,5-
epoxide (Fig. 1) which can form another adduct with guanine (Schoket et al., 1989; Nesnow 
et al., 1993; Fang et al., 2003). Thus, the levels and activities of CYP1A1 seem to be crucial 
both for the initiation of BaP-mediated carcinogenesis and BaP detoxification. The expression 
of CYP1A1 is known to be up-regulated by the aryl hydrocarbon receptor (AHR) and BaP can 
bind to and activate AHR thereby enhancing its own metabolic activation (Hockley et al., 
2007).  
The level of BaP-DNA adducts in cells is most probably the result of a balance between 
their formation and their loss through either DNA repair processes, or cell turnover. 
Collectively, BaP genotoxicity depends on various factors: (i) metabolism of BaP by phase I 
enzymes (activation) to reactive DNA-binding species; (ii) detoxification of reactive BaP 
metabolites by both phase I and phase II enzymes (conjugation); (iii) rate of repair of BaP-
DNA adducts; and (iv) BaP-induced expression of genes such as those encoding enzymes 
involved in activation/detoxification or in DNA damage response (Uno et al., 2004). 
Recently, controversial results have been found showing a more important role of 
CYP1A1 in BaP detoxification in vivo than in its activation (Uno et al., 2004; 2006; Arlt et 
al., 2008; 2012). Cyp1a1(−/−) mice treated with repeated oral doses of BaP (125 mg/kg body 
weight [bw]/day), die within ~28 days due to immune suppression, whereas wild-type (WT) 
mice remain healthy for at least 1 year on this regimen (Uno et al., 2004). Using the Hepatic 
P450 Reductase Null (HRN) and the Reductase Conditional Null (RCN) mouse models we 
also showed that hepatic CYP enzymes appear to be more important for detoxification of BaP 
in vivo (Arlt et al., 2008; 2012). In these mice NADPH:P450 oxidoreductase (POR), the 
essential electron donor to CYPs is deleted specifically in hepatocytes, resulting in a decrease 
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in hepatic CYP function (Henderson et al., 2003; Finn et al., 2007). We found however that 
the levels of dG-N2-BPDE adducts in livers of these mice treated with BaP were higher than 
in WT mice (Arlt et al., 2008; 2012). 
We postulate that the reason for these unexpected findings could be found in vitro by 
analyzing the roles of the different contributing enzymes at different ratios to each other. This 
can be achieved in reconstituted systems where single enzymes can be added at definite 
amounts without interference from other constituents as in microsomal systems. These data 
were compared with the metabolism of BaP and its activation to BaP-DNA adducts in vivo. 
We evaluated CYP1A1-mediated BaP metabolism and its bioactivation in mouse hepatic 
microsomes and by recombinant CYP1A1 reconstituted with POR. Because microsomal 
cytochrome b5 has been found to participate in transfer of electrons to CYP enzymes during 
the CYP catalysis or cause allosteric changes in CYP protein structures that can augment the 
CYP mediated reactions (Porter, 2002; Schenkman and Jansson, 2003; Guengerich, 2005; 
Stiborová et al., 2006; 2012; Kotrbová et al., 2011; Riddick et al., 2013), we also analyzed its 
effects on BaP oxidation in the reconstituted system of CYP1A1 with POR. Moreover, since 
mEH is essential for the formation of the dG-N2-BPDE adduct (Kim et al., 1998; Baird et al., 
2005), its influence upon BaP-DNA adduct levels formed in a CYP1A1 reconstituted system 
was also elucidated. The levels of CYP1A1, POR, cytochrome b5 and EH in mouse hepatic 
microsomes were determined in previous studies (Arlt et al., 2008; 2012). In the present work, 
we used a wide range of various ratios of these enzymes in the reconstituted systems to 
analyze their individual contribution to oxidation/activation of BaP. Among them, at least the 
reconstitution systems containing low concentrations of POR likely mimic the situation in the 
tested hepatic microsomes or in vivo. The formation of BaP metabolites was measured by 
high pressure liquid chromatography (HPLC) with UV-detection. DNA adduct formation was 
investigated by the thin-layer chromatography (TLC)-32P-postlabeling method. 
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2. Material and Methods  
2.1. Chemicals  
BaP (>96%) was purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals 
were of analytical purity or better.  
2.2. Animal experiments  
All animal experiments were carried out under license in accordance with the law, and 
with local ethical approval. HRN (Porlox/lox/CreALB) mice on a C57BL/6 background were 
derived as described previously (Henderson et al., 2003). BaP was dissolved in corn oil at a 
concentration of 12.5 mg/ml. Groups of female HRN mice (3 months old, 25-30 g, n=3) were 
treated intraperitoneally with 125 mg/kg bw of BaP for five days. Control mice received corn 
oil only (Arlt et al., 2008). Animals were killed 24 h after the last dose. Livers were removed, 
snap frozen and stored at −80oC until analysis. 
2.3. Preparation of microsomes  
Hepatic microsomes were isolated as described previously (Arlt et al., 2008) and pooled 
for further experiments. Protein concentration in the microsomal fraction was measured using 
bicinchoninic acid protein assay (Wiechelman et al., 1988) with bovine serum albumin as a 
standard.  
2.4. Isolation of CYP1A1, POR, cytochrome b5 and mEH 
Recombinant rat CYP1A1 protein was purified to homogeneity from membranes of 
Escherichia coli transfected with a modified CYP1A1 cDNA (Stiborová et al., 2002), in the 
laboratory of H. W. Strobel (University of Texas, Medical School of Houston, Texas, USA) 
by P. Hodek (Charles University, Prague, Czech Republic). Rabbit liver POR was purified as 
described (Stiborová et al., 2002). Cytochrome b5 was isolated from rabbit liver microsomes 
by the procedure described by Roos (1996). mEH was purified from liver microsomes of 
rabbits pretreated with phenobarbital as described by Ariyoshi et al. (1994). These enzymes 
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were used for the CYP1A1 reconstitution experiments. As shown in our previous studies 
(Stiborová et al., 2002; 2004; 2006; 2012; Kotrbová et al., 2009; 2011), the enzymatic activity 
of rat or human CYP1A1 reconstituted with rabbit POR and cytochrome b5 was essentially 
the same as that of the enzyme reconstituted with the rat orthologs of these enzymes.  
2.5. Microsomal and enzymatic incubations 
Incubation mixtures used to  study BaP metabolism in mouse hepatic microsomes or by 
purified CYP1A1 (100 pmol) reconstituted with POR (5-150 pmol), with or without 
cytochrome b5 (100-500 pmol), with or without mEH (20-250 pmol) contained 100 mM 
potassium phosphate buffer (pH 7.4), NADPH-generating system (1 mM NADP+, 10 mM 
D-glucose-6-phosphate, 1 U/ml D-glucose-6-phosphate dehydrogenase), 0.5 mg of 
microsomal protein or 100 pmol CYP1A1 in the reconstituted system, 50 µM BaP (dissolved 
in 5 µl dimethyl sulfoxide) in a final volume of 500 µl. The enzyme reconstitution was 
performed as described [(Stiborová et al., 2002; 2006; Kotrbová et al., 2011), using different 
molar ratios of CYP1A1 to POR and cytochrome b5 and/or mEH (see Results for details). 
Briefly, purified CYP1A1 was reconstituted with pure POR as follows (2 µM CYP, 0.1-3 µM 
POR, 0.5 µg/µl CHAPS, 0.1 µg/µl liposomes [dilauroyl phosphatidylcholine, dioleyl 
phosphatidylcholine, and dilauroylphosphatidylserine (1:1:1)], 3 mM reduced glutathione, and 
50 mM HEPES/KOH, pH 7.4). The reaction was initiated by adding 50 µl of the 
NADPH-generating system. Control incubations were carried out either without enzymatic 
system (microsomes or the CYP1A1-reconstituted system), or without NADPH-generating 
system, or without BaP. After incubation (37°C, 20 min), 5 µl of 1 mM phenacetin (PA) in 
methanol was added as an internal standard. BaP metabolites were extracted twice with ethyl 
acetate (2 × 1 ml), solvent evaporated to dryness, residues dissolved in 25 µl methanol and 
BaP metabolites separated by HPLC. 
Incubation mixtures used to analyze BaP-induced DNA adduct formation were as 
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described above but contained 1 mM NADPH instead of the NADPH-generating system plus 
1 mg calf thymus DNA. The reaction was initiated by adding BaP. Incubations were carried 
out at 37°C for 90 min; BaP-DNA adduct formation was linear up to 120 min (Arlt et al., 
2008). Control incubations were carried out either without CYP, without NADPH, without 
DNA, or without BaP. After the incubation, DNA was isolated from the residual water phase 
by the phenol/chloroform extraction method as described (Stiborová et al., 2002). 
2.6. CYP1A1 enzyme activity assays 
The samples containing CYP1A1 reconstituted with POR (see the procedure described 
above) were characterized for enzyme activity using Sudan I oxidation for CYP1A1 
(Stiborová et al., 2002) and 7-ethoxyresorufin O-deethylation (EROD) for CYP1A 
(Guengerich and Shimada, 1991). 
2.7. HPLC analysis of BaP metabolites 
HPLC analysis of BaP metabolites was performed on a Nucleosil C18 reverse phase 
column, (250 × 4 mm, 5 µm; Macherey Nagel, Düren, Germany) using a Dionex system 
consisting of a pump P580, a UV/VIS Detector UVD 170S/340S, an ASI-100 Automated 
Sample Injector, a termobox COLUMN OVEN LCO 101 and an In-Line Mobile Phase 
Degasser Degasys DG-1210 Dionex controlled with ChromeleonTM 6.11 build 490 software. 
The conditions used for the chromatographic separation of BaP metabolites were as follows: 
50% acetonitrile in water; (v/v), with a linear gradient to 85% acetonitrile in 35 min, then an 
isocratic elution with 85% acetonitrile for 5 min, a linear gradient from 85% acetonitrile to 
50% acetonitrile in 5 min, followed by an isocratic elution of 50% acetonitrile for 5 min. 
Detection was by UV absorption at 254 nm. BaP metabolite peaks (Fig. 2A) were collected 
and analyzed by NMR and/or mass spectrometry.  The areas under the curve at 254 nm were 
calculated relative to the peak area of the internal standard phenacetin and expressed as 
relative peak areas. 
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2.8. NMR spectrometry 
 NMR spectra (δ, ppm; J, Hz) of BaP and its metabolites M1, M4, M5 and M7 were 
measured on a Bruker Avance II-600 and/or Bruker Avance II-500 instruments equipped with 
a cryoprobe (600.1 or 500.0 MHz for 1H and 150.9 or 125.7 MHz for 13C) in hexadeuterated 
acetone and CDCl3 and referenced to the solvent signals (δ 2.05 and 7.27, respectively). Due 
to the low amounts of metabolites it was not possible to acquire 13C NMR spectra or perform 
heteronuclear correlation experiments.  
1) BaP. 1H NMR spectrum of BaP contains five isolated spin systems: one three-spin 
system of hydrogens H-1, H-2 and H-3, one four-spin system of H-7, H-8, H-9 and H-10, one 
isolated spin of H-6 and two two-spin systems of H-4, H-5 and of H-11, H-12. The 
assignment of signals in the spectrum could be done with the help of homonuclear COSY 
spectrum, where strong cross-peaks corresponding to three-bond couplings were observed. 
However, the signals of the two two-spin systems (H-4,H-5 and H-11, H-12) could not be 
assigned with the use of COSY spectrum only and heteronuclear correlation spectra (HSQC 
and HMBC) had to be used. The assignment of all 1H signals and coupling constants of BaP 
and its metabolites is shown in Table 1 (for structures see Fig 2B). 
2) M1. Two signals of the four-spin system of M1 were shifted upfield (to 4.5 and 5.7 
ppm). These values are too low for the fully aromatic BaP skeleton. The structure of M1 was 
identified as trans-9,10-dihydro-BaP-9,10-diol (BaP-9,10-dihydrodiol) by comparison with 
previously reported NMR data of this compound (Platt and Oesch, 1983). The trans 
arrangement of the two hydroxy groups was supported by the inspection of the vicinal 
coupling constant between hydrogen atoms H-9 and H-10. The torsion angle between these 
two hydrogen atoms calculated using the generalized Karplus type equation (Haasnoot et al., 
1980) was predicted to be 48º. This value is very close to the torsion angle observed in the 
molecular model of the trans-derivative with the two hydroxyl groups in pseudo-axial 
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positions. The molecular model of the cis-derivative predicts the torsion angle between the 
two hydrogen atoms to be close to −75º. We were unable to determine the absolute 
configuration on the new asymmetric centers (C-9 and C-10). It is possible that both 
enantiomers are present in metabolite M1. 
3) M4 and M5. In the spectra of both compounds we observed the four-spin system of H-
7, H-8, H-9 and H-10 and three two-spin systems. Two substituents are therefore attached to 
the BaP skeleton: one in position 6 and the second one in position 1 or 3. Furthermore, the 
unusually shielded H-2 proton at 6.7 ppm was characteristic of the α-proton (next to 
carbonyl) in phenalones (Prinzbach  et al., 1967) suggesting that the structures of M4 and M5 
could be BaP-1,6-dione and -3,6-dione, respectively. Because both compounds were 
synthesized previously and their 1H NMR spectra was reported (Leeruff et al., 1986; Xu et al., 
2009), spectra in CDCl3 were used for comparison and the metabolites could be identified as 
BaP-1,6-dione (M4) and BaP-3,6-dione (M5). 
4) M7. In the spectrum of M7, the three-spin system was replaced with a two-spin system 
suggesting that one substituent is attached to the position 1 or 3 of the BaP. The structure of 
M7 was confirmed to be BaP-3-ol by comparison of the chemical shifts and coupling 
constants with those reported previously (Xu et al., 2009).  
5) M2, M3 and M6. Because the amounts of M2, M3 and M6 samples were insufficient 
for NMR spectroscopy, these metabolites were analyzed only by mass spectrometry only as 
described below. 
2.8. Mass spectrometry 
Mass spectra of BaP and its metabolites M2, M3 and M6 were measured on a matrix-
assisted laser desorption/ionisation reflectron time-of-flight MALDITOF mass spectrometer 
ultraFLEX III (Bruker-Daltonics, Bremen, Germany). Positive spectra were calibrated 
externally using the monoisotopic [M+H]+ ion of MRFA peptide 524.26 m/z and CCA matrix 
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peaks 190.05, 379.09 m/z. A 10 mg/ml solution of α-cyano-4-hydroxy-cinnamic acid or 2,5-
dihydrobenzoic acid in 50% MeCN/0.3% acetic acid was used as MALDI matrix. A 0.5 µl of 
sample dissolved in MeCN was premixed with 0.5 µl of the matrix solution on the target and 
allowed to dry at ambient temperature. The MALDI-TOF positive spectra were collected in 
reflectron mode. Positive [M+] of BaP corresponded to this compound (m/z 252.1). The 
metabolites with retention times of 11.9 (M2) and 12.9 min (M3) gave a positive molecular 
ion each at m/z 286.1 which is indicative of BaP-dihydrodiol metabolites. The metabolite 
eluted at 24.6 min (M6) gave a positive molecular ion at m/z 268.1 which is indicative of a 
hydroxylated BaP metabolite. These results are consistent with previous studies on the 
metabolism of BaP by human CYP1A1 (Bauer et al., 1995; Kim et al., 1998), in which these 
metabolites were identified as BaP-4,5-dihydrodiol (M2), BaP-7,8-dihydrodiol (M3), and 
BaP-9-ol (M6). 
2.9. BaP-DNA adduct detection by 32P-postlabeling analysis 
DNA adducts were measured using the nuclease P1 enrichment version of the TLC-32P-
postlabeling method essentially as described previously (Arlt et al., 2008; Phillips and Arlt, 
2007). Briefly, DNA samples (4 µg) were digested with micrococcal nuclease (120 mU; 
Sigma) and calf spleen phosphodiesterase (40 mU; Calbiochem), enriched and labeled as 
reported. Solvent conditions for the resolution of 32P-labeled adducts on polyethyleneimine-
cellulose (PEI) TLC were: D1, 1.0 M sodium phosphate, pH 6; D3, 4.0 M lithium-formate, 
7.0 M urea, pH 3.5; D4, 0.8 M lithium chloride, 0.5 M Tris, 8.5 M urea, pH 8. After D3 or D4 
developments to the top of the plates, the plates were developed an additional 30 min with the 
TLC tank partially opened, to prolong the resolution time of the BaP-DNA adducts. After 
chromatography TLC plates were scanned using a Packard Instant Imager (Dowers Grove, IL, 
USA). DNA adduct levels (RAL, relative adduct labeling) were calculated as described (Arlt 
et al., 2008). Results were expressed as DNA adducts/108 nucleotides. An external BPDE-
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DNA standard (Phillips and Castegnaro, 1999) was employed to identify adducts in 
experimental samples.  
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3. Results 
3.1. Oxidation of BaP by hepatic microsomes and CYP1A1 reconstituted with POR, 
cytochrome b, and mEH 
BaP metabolism in the CYP1A1 reconstituted system containing POR combined with 
cytochrome b5 and/or mEH was compared with its metabolism by hepatic microsomes 
isolated from control (untreated) and BaP-pretreated HRN mice. In studies using mouse 
hepatic microsomes, a spectrum of hydroxylated BaP metabolites, BaP-dihydrodiols as well 
as BaP diones (quinones) was found (Fig. 2). Seven BaP oxidation products (designated as 
M1-M7) were generated both by hepatic microsomes of control HRN mice and by those with 
induced CYP1A1 expression mediated by pretreating HRN mice with BaP. These metabolites 
have been reported to be formed by CYP1A1 in combination with mEH (Bauer et al., 1995; 
Kim et al., 1998; Baird et al., 2005). The HPLC method using an acetonitrile/water gradient 
as mobile phase and UV detection at 254 nm resulted in mostly base-line separation of all 
BaP metabolites (Fig. 2A).  
The BaP metabolites formed by mouse hepatic microsomes were collected and 
subsequently characterized by NMR or mass spectrometry. They were identified to be BaP-
9,10-dihydrodiol (M1), BaP-4,5-dihydrodiol (M2), BaP-7,8-dihydrodiol (M3), BaP-1,6-dione, 
(M4), BaP-3,6-dione (M5), BaP-9-ol (M6), and BaP-3-ol (M7) (see Fig. 2). Very low 
expression levels of mouse Por in the liver of untreated HRN mice that constitutively express 
Cyp1a1 (Arlt et al., 2008) resulted in the formation of very low amounts of these BaP 
metabolites. However, Cyp1a1 induction by BaP pretreatment of HRN mice (Arlt et al., 2008) 
was sufficient for the effective oxidation of BaP by hepatic microsomes, even at the very low 
Por concentrations in these microsomes (Fig. 3). The efficiency of these microsomes to 
oxidize BaP to BaP-7,8-dihydrodiol, the precursor of BPDE, was more than 34-fold higher 
than that of microsomes of untreated mice, while formation of other metabolites was less 
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pronounced. Amounts of BaP-9,10-dihydrodiol, BaP-4,5-dihydrodiol, BaP-1,6-dione, BaP-
3,6-dione, BaP-9-ol and BaP-3-ol were 6.6-, 9.6-, 2-, 3.4-, 10- and 7.7-times higher, 
respectively, in microsomes of HRN mice exposed to BaP than in those of untreated HRN 
mice  (Fig. 3).  
To investigate the role of CYP1A1 in oxidation of BaP to individual metabolites, purified 
CYP1A1 was reconstituted with POR and used as the oxidation system. CYP1A1 
reconstituted with POR was active with its typical substrates, Sudan I (Stiborová et al., 2002) 
and 7-ethoxyresorufin (Guengerich and Shimada, 1991) (data not shown). Isolated CYP1A1 
reconstituted with POR oxidized BaP to only four metabolites, namely BaP-1,6-dione (M4), 
BaP-3,6-dione (M5), BaP-9-ol (M6), and BaP-3-ol (M7) (Fig. 4). As expected, no BaP-
dihydrodiols were detected in this system because of the absence of mEH which is important 
for the hydration of BaP epoxides. In the enzymatic systems where mEH was reconstituted 
with CYP1A1 and POR, BaP-9,10-dihydrodiol (M1) and BaP-7,8-dihydrodiol (M3) were 
formed as expected, however the whole metabolic profile of BaP could not be quantified 
because some impurities in the mEH preparation interfered with BaP metabolites eluting 
between 22 and 35 min during HPLC (data not shown).  
Interestingly, no significant differences in levels of BaP-1,6-dione, BaP-3,6-dione and 
BaP-9-ol were found in the systems where CYP1A1 was reconstituted with low amounts of 
POR (the CYP1A1:POR ratio was 1:0.05) or equimolar concentrations of these enzymes  
(Fig. 4). Only BaP-3-ol formation was significantly higher (1.6-fold) in the system containing 
equimolar CYP1A1:POR ratios. No BaP metabolites were formed when POR was omitted 
from the CYP1A1 reconstitution system (Fig. 4). However, when CYP1A1 was reconstituted 
with cytochrome b5 without POR (under CYP1A1:cytochrome b5 ratios of 1:1, 1:2.5 or 1:5), 
BaP was oxidized (Fig. 5A) to only low amounts of BaP-9-ol. Addition of cytochrome b5 to 
the CYP1A1/POR reconstituted system led to a cytochrome b5-concentration-dependent 
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increase in BaP oxidation (compare Fig. 4 and Fig. 5B and C); the increase was found both at 
1:0.05 and 1:1 CYP1A1:POR ratios. BaP-3-ol was the major metabolite formed under both 
CYP1A1:POR ratios but its amount was up to 1.8-fold higher when POR was present at an 
equimolar ratio to CYP1A1 than at the 1:0.05 CYP1A1:POR ratio. In contrast, the amount of 
BaP-9-ol was always higher in the system with low POR concentrations. Like BaP-3-ol, the 
amount of BaP-3,6-dione formed in the system was always higher at equimolar 
CYP1A1/POR concentrations relative to the systems containing low POR concentrations, 
while overall no differences were found for BaP-1,6-dione. Collectively, all these results 
indicate that cytochrome b5 may contribute quite substantially to the CYP1A1-mediated 
oxidation of BaP, even under conditions with very low quantities of POR.  
3.2. BaP-DNA adduct formation by hepatic microsomes and CYP1A1 reconstituted with POR, 
cytochrome b5 and mEH 
In further experiments the formation of BaP-derived DNA adducts was investigated in 
analogous enzymatic systems.  
Activation of BaP by CYP1A1 reconstituted with POR in the presence of DNA resulted in 
the formation of only one BaP-DNA adduct (adduct spot 1 shown in Fig. 6A). Therefore, this 
adduct is formed by CYP1A1-catalyzed oxidation of BaP, without the contribution of mEH. 
Comparison with previous 32P-postlabeling studies (Schoket et al., 1989; Nesnow et al., 1993; 
Fang et al., 2001) showed that adduct spot 1 has similar chromatographic properties on PEI-
cellulose TLC to a guanine adduct derived from reaction with 9-hydroxy-BaP-4,5-epoxide 
(see Fig. 1). In accordance with these previous results, DNA adduct 1 (Fig. 6) had more 
hydrophobic properties on PEI-cellulose than another BaP-derived DNA adduct (assigned 
adduct spot 2) formed by hepatic microsomes (compare Fig. 6D), which was identified as dG-
N2-BPDE (Schoket et al., 1989; Fang et al., 2001; Arlt et al., 2008). 
As shown in Figure 7A formation of BaP-DNA adduct 1 was dependent on the 
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CYP1A1:POR ratio and was formed even at low POR concentrations (i.e. a CYP1A1:POR 
ratio of 1:0.2). However, when BaP was incubated with DNA using a CYP1A1:POR ratio of 
1:2, lower levels of this adduct were produced (Fig. 7A). Addition of increasing amounts of 
mEH to the CYP1A1/POR reconstituted system led to a decrease in the formation of this 
adduct, while BaP-DNA adduct 2 (adduct spot 2 shown in Figure 6B and 6D) was generated 
(Figs. 7B, 8A and 8C). No BaP-DNA adducts were detected by 32P-postlabeling when 
NADPH, the cofactor of the NADPH-dependent CYP system, was omitted from incubations 
with the CYP1A1 reconstituted systems (Fig. 6C). 
Addition of cytochrome b5 to the CYP1A1 reconstituted system resulted in increased 
formation of both BaP-DNA adducts formed under a CYP1A1:POR ratio of 1:2, both in the 
absence and presence of mEH (Fig. 8). However, levels of BaP-DNA adduct 1 at a 
CYP1A1:POR ratio of 1:0.2 were nearly identical in the presence or absence of cytochrome 
b5 when mEH was absent, whereas addition of cytochrome b5 to this system in the presence of 
mEH increased formation of both BaP-DNA adducts (Figs. 8A and B). The levels of adduct 1 
formed by CYP1A1, POR and cytochrome b5 in a ratio of 1:2:3 were higher than in any other 
enzyme combination (Fig. 8). Among all enzyme combinations used, the highest levels of 
both BaP-DNA adducts were produced by the system containing CYP1A1, POR, mEH and 
cytochrome b5 in a ratio of 1:2:0.5:3 (Fig. 8D) followed by the systems containing these 
enzymes in ratios of 1:0.2:1:3 (Fig.  8B) or 1:2:1:3 (Fig. 8D). These results showed that even 
under low POR concentrations, CYP1A1 in the presence of appropriate concentrations of 
mEH and cytochrome b5 efficiently activates BaP to DNA binding species. These results are 
in line with the BaP metabolite profile in the CYP1A1 reconstituted experimental systems 
described above.  
The DNA adduct results obtained in reconstituted enzyme systems corresponded to those 
found in hepatic microsomes of HRN mice. As shown in our previous study (Arlt et al., 
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2008), incubation of BaP with hepatic microsomes from these mice led to DNA adducts 
detectable by 32P-postlabeling. Using this method one major asymmetric BaP-DNA adduct 
spot was detectable, in which the dG-N2-BPDE adduct was identified by cochromatographic 
analysis, and DNA adduct levels increased substantially in incubations with microsomes from 
BaP pretreated HRN mice (Arlt et al., 2008). After closer inspection of this asymmetric BaP-
DNA adduct spot and improved chromatographic separation, two major BaP-DNA adducts 
(still partially overlapping one another) were detectable. Better separation of these BaP-DNA 
adducts as well as those found in liver of HRN mice treated with BaP was achieved on PEI-
cellulose TLC (Fig. 6D and 6E) by a slightly modified development in D3 and D4 directions 
as outlined in Material and Methods. The chromatographic properties of both adducts on TLC 
were similar to the two BaP-DNA adducts found in experiments utilizing CYP1A1-
reconstituted systems (compare adduct spots 1 and 2 in Fig. 6B and 6D). Therefore, in the 
present study we re-analyzed the BaP-DNA adduct levels found in hepatic microsomal 
incubations from control (untreated) HRN mice and those pretreated with BaP. While only 
low levels of both BaP-DNA adducts were formed by hepatic microsomes from untreated 
HRN mice, formation of both adducts increased substantially (~50-fold) in hepatic 
microsomes isolated from BaP-pretreated HRN mice (Fig. 9). These results indicate that 
Cyp1a1 induction in combination with relative low Por expression still provides an efficient 
BaP activation system leading to DNA adduct formation. BaP-DNA adduct 1 was, however, 
hardly detectable in liver DNA from BaP-treated HRN mice (Fig. 6E) which is in full 
concordance with results obtained previously (Arlt et al., 2008) where dG-N2-BPDE (assigned 
BaP-DNA adduct 2 in the present study) was the major adduct identified in vivo.  
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4. Discussion 
Previously we worked with two different mouse models lacking Por expression in 
hepatocytes and found that the levels of BaP-DNA adducts were up to 13-fold higher in livers 
of HRN mice treated with BaP than in those of WT mice (Arlt et al., 2008). More recently, 
these results were confirmed in the RCN mouse model (Arlt et al., 2012), indicating that 
hepatic CYP enzymes are more important for detoxification of BaP in vivo despite being 
required for its bioactivation in vitro. Nevertheless, hepatic microsomes from HRN mice 
expressing very low Por levels, and particularly those from BaP-pretreated HRN mice were 
capable of activating BaP to form DNA adducts in vitro (compare Fig. 6 in Arlt et al., 2008 
and Figs. 6D and 9 in the present work), suggesting that Cyp1a1-mediated bioactivation of 
BaP takes place in these microsomes. In order to confirm this finding in a flexible modular 
experimental system we investigated the oxidative metabolism of BaP and its bioactivation to 
BaP-DNA adducts in a reconstituted enzyme system that allows the addition and removal of 
individual enzymes. Purified CYP1A1 was reconstituted with POR and other components of 
the microsomal enzymatic system (cytochrome b5 and mEH) in various combinations and 
ratios were employed. For comparison mouse microsomal enzymatic systems were utilized.  
Among the tested reconstituted systems, at least those containing low concentrations of POR 
likely mimic the situation in mouse hepatic microsomes or in vivo. However, it should be 
noted that the reconstituted systems may only provide mechanistic insights and cannot be 
fully extrapolated to microsomes and/or to the in vivo situation. 
Interestingly, as shown in Figures 2 and 3 the results obtained in the present study 
demonstrated that BaP is oxidized by hepatic microsomes of control (untreated) and BaP-
pretreated HRN mice containing very low amounts of Por to hydroxylated BaP metabolites 
(BaP-3-ol and BaP-9-ol), BaP-dihydrodiols (BaP-4,5-dihydrodiol, BaP-7,8-dihydrodiol and 
BaP-9,10-dihydrodiol) as well as BaP diones (BaP-1,6-dione and BaP-3,6-dione). The same 
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metabolites have been formed in several previous studies utilizing enzyme systems of 
CYP1A1 combined with POR and mEH (Kim et al., 1998; Jiang et al., 2007; Zhu et al., 
2008). We also found that BaP is activated by these microsomes to form BaP-DNA adducts 
(Fig. 6) which have been detected in previous studies (Nesnow et al., 1993; Schoket et al., 
1989; Fang et al., 2001; Siddens et al., 2012).  
As expected, mEH was essential for the formation of BaP-dihydrodiols; CYP1A1 
reconstituted with POR but without mEH generated only BaP-1,6-dione, BaP-3,6-dione, BaP-
3-ol, and BaP-9-ol. It is known that oxidation of various substrates by CYP1A1 or other 
CYPs is dependent on the POR:CYP1A1 ratio; optimal ratios of these enzymes are usually 
1:1 or higher (Buters et al., 1995; Chun et al., 1996; Schwarz et al., 2001; Shimada et al., 
1999; 2001; 2004; Yamazaki et al., 2001; Stiborová et al., 2002; Guengerich, 2005; Faroog 
and Roberts, 2010; Davydov, 2011; Kotrbová et al., 2011; Davydov et al., 2013). 
Interestingly, in contrast to these findings, with the exception of BaP-3-ol, formation of BaP 
metabolites by CYP1A1 reconstituted with POR was the same, even when the CYP1A1:POR 
ratio was only 1:0.05. This CYP1A1:POR ratio essentially mimics the expression level of 
these enzymes in the livers of HRN mice (Arlt et al., 2008), while a higher than equimolar 
POR:CYP1A1 ratio more reflects the situation in the livers of WT mice suggesting an 
effective transfer of electrons from NADPH to the CYP1A1-BaP binary complex mediated by 
POR. The only detoxification BaP metabolite, BaP-3-ol, was formed at higher amounts in the 
CYP1A1 system reconstituted with an equimolar ratio of POR. This high efficiency of BaP 
metabolism at ratios of CYP1A1:POR of less than 0.5 are unusual, but seems to be a specific 
phenomenon for oxidation of BaP by CYP1A1 rather than a general feature. For other 
substrates such as Sudan I (Stiborova et al., 2002) and ellipticine (Mrazova et al., 2007, 
Kotrbova et al., 2011) a reconstitution system of CYP1A1 with POR at a ratio of 1:1 was 
optimal. It seems that binding of BaP to CYP1A1 mediating formation of the high-spin state 
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of CYP1A1 facilitates the enzyme oligomerization (aggregation) in an artificial membrane of 
liposomes and such CYP1A1-CYP1A1 interactions may have evolved to optimize the 
functioning of the reconstitution system at limiting concentrations of POR. Indeed, there 
are numerous observations demonstrating a crucial effect of oligomerization of 
microsomal CYPs on their functional properties. One of the most prominent consequences 
of oligomerization is given by “persistent heterogeneity” or apparent divergence of a pool 
of a single CYP species into non-interconverting and functionally separate fractions 
(Davydov, 2011). This suggestion was supported by several investigations for substrate 
oxidation by various CYP enzymes in the reconstituted systems (Kaminsky and 
Guengerich, 1985; Backes et al., 1989; Iwase et al., 1991; Fernando et al., 2007; 2008; 
Davydov, 2011). The reasons for the results found in the present work seem to be even more 
complex, as BaP oxidation by the CYP1A1 reconstituted system was substantially stimulated 
by cytochrome b5.  
The major BaP-DNA adduct formed in HRN/RCN mice and in hepatic microsomes of 
HRN mice was previously identified by TLC, HPLC and LC-MS/MS to be dG-N2-BPDE. In 
addition, another adduct found and assigned adduct 1 in the present study, exhibited more 
hydrophobic properties on 32P-postlabeling TLC (see Fig. 1 in Arlt et al., 2008 and Fig. 2 in 
Arlt et al., 2012) and could be separated from adduct 2 (i.e. dG-N2-BPDE). Since mouse 
hepatic Cyp enzyme activity had been largely obliterated by the permanent (HRN model) or 
conditional (RCN model) deletion of Por in hepatocytes, the levels of BaP-DNA adduct 
formation in livers in HRN or RCN mice in vivo and in hepatic microsomes of HRN mice ex 
vivo was difficult to rationalize (Arlt et al., 2008; 2012). Previous results indicated that the 
process leading to DNA adducts did not involve the generation of a reactive species different 
from that formed in WT mice (Arlt et al., 2008; 2012). Since the structure of the dG-N2-BPDE 
adduct formed in vivo was identified by mass spectrometry (Arlt et al., 2008), BPDE (Fig. 1) 
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must be the reactive species formed both in HRN/RCN and WT mice. Moreover, enzymes 
different from CYPs such as cyclooxygenases were not found to be involved in BaP 
activation in these mouse models (Arlt et al., 2008). Indeed, formation of dG-N2-BPDE by 
hepatic microsomes of HRN mice ex vivo, which depended on NADPH, and was attenuated 
by inhibitors of CYP1A1 (α-naphthoflavone, ellipticine) and POR (α-lipoic acid), supported 
this conclusion (Arlt et al., 2008). Although the CYP specificity of chemical inhibitors can 
sometimes be problematic (Rendic and DiCarlo, 1997), these results indicated that hepatic 
Cyp1a1 in combination with even a very low Por expression level can be responsible for the 
formation of BaP-DNA adducts in hepatic microsomes of HRN mice.  
 Induction of Cyp1a1 in HRN mice with BaP resulted in a more than 34-fold increase in 
the production of BaP-7,8-dihydrodiol in ex vivo incubations of BaP with such microsomes 
relative to microsomes of untreated mice. BaP-7,8-dihydrodiol is the precursor of BDPE 
which subsequently can generate the dG-N2-BPDE adduct, explaining the formation of the 
dG-N2-BPDE adduct in the microsomes of HRN mice pretreated with BaP (Arlt et al., 2008 
and present work]. In contrast, BaP-3-ol the major CYP1A1-mediated metabolite detoxicating 
BaP (Baird et al., 2005) only increased 7.7-fold after pretreatment of mice with BaP.  
In this study two DNA adducts were generated by hepatic microsomes of HRN mice and 
levels of both were dependent on pretreatment of these mice with BaP, a CYP1A1 inducer. 
When CYP1A1 reconstituted with POR only was used for BaP activation, one BaP-DNA 
adduct (assigned adduct 1; Fig. 6A) was generated. After addition of mEH to the 
CYP1A1/POR reconstituted system, the dG-N2-BPDE adduct (assigned adduct 2; Fig. 6) was 
also formed. Again, higher amounts of both BaP-DNA adducts were formed by CYP1A1 in 
the presence of low POR levels (i.e. a ratio of CYP1A1:POR of 1:0.2) than at equimolar ratios 
in the reconstitution system. Moreover, cytochrome b5 substantially stimulated BaP-DNA 
adduct formation. Both these BaP-DNA adducts have also been found by Schoket et al. 
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(1989) and Fang et al. (2001) to be generated by rat hepatic microsomes and separated as two 
adduct spots by TLC-32P-postlabeling. The highly hydrophobic adduct 1 was tentatively 
identified by these authors as an adduct derived from 9-hydroxy-BaP-4,5-epoxide. This BaP 
metabolite is bound to the exocyclic amino group of a guanine residue, and the site of 
attachment is most likely either the 4 or the 5 position of BaP (Fang et al., 2003). Analogous 
to our results, the formation of adduct 1 was independent of the activity of mEH; an inhibitor 
of this enzyme, 1,2-epoxy-3,3,3-trichloropropane, did not influence its formation (Schoket et 
al., 1989). In contrast the formation of dG-N2-BPDE (adduct 2) was strongly inhibited by this 
mEH inhibitor. Nevertheless, even though a precursor of 9-hydroxy-BaP-4,5-epoxide, BaP-9-
ol, was formed both in mouse hepatic microsomes and by the CYP1A1 reconstitution system, 
further work is required to demonstrate that adduct 1 is derived from 9-hydroxy-BaP-4,5-
epoxide. The synthesis of an authentic standard should help with the structural identification.  
It is well known that BaP is a strong CYP1A1 inducer in many organisms including HRN 
mice (Arlt et al., 2008). BaP also induced expression of Por protein (by 2.9-fold) and the 
activity of this enzyme as well as mEH and cytochrome b5 in HRN mice (Arlt et al., 2008; 
2012), thereby enhancing its own metabolic activation. Indeed, pretreatment of HRN mice 
with BaP led to more than ~50-fold higher DNA adduct levels ex vivo using hepatic 
microsomes (Fig. 9). Because microsomal cytochrome b5 influences the CYP1A1-mediated 
activation of BaP in vitro, and is induced by BaP treatment in HRN mice (Arlt et al., 2012), 
this protein can modulate Cyp1a1-catalyzed activation of BaP also in this mouse model in 
vivo. Several mechanisms of cytochrome b5-mediated modulation of CYP catalysis have been 
suggested. One of them suggests a role of cytochrome b5 in the direct transfer of the second 
electron to the CYP enzyme, which is considered to be the rate limiting step in the catalytic 
cycle of the CYP monooxygenase reaction. The electron transfer from reduced cytochrome b5 
to CYP is faster than the input of electrons from POR. Due to this stimulation effect CYPs are 
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prevented from uncoupling of partially activated oxygen. Moreover, the addition of 
cytochrome b5 enhances the stability of the oxy-CYP complex, therefore a higher amount of 
activated oxygen is available to form hydroxylated products. Another possible mechanism of 
the cytochrome b5 action is the formation of a complex between cytochrome b5 and CYP, 
which can receive two electrons from POR in a single step, one for reduction of CYP and 
another for that of cytochrome b5. While CYP without cytochrome b5 has to undergo two 
separate interactions with POR to complete one catalytic cycle, in the presence of cytochrome 
b5 a single interaction of the complex of CYP and cytochrome b5 with POR is sufficient; 
cytochrome b5 provides the second electron to CYP promptly after oxygen binding. 
Cytochrome b5 can also act as an allosteric modifier of the oxygenase (Porter, 2002; 
Schenkman and Jansson, 2003; Guengerich, 2005; Kotrbová et al., 2011; Stiborová et al., 
2012; Riddick et al., 2013). Thus, in HRN mice cytochrome b5 may not only modulate the 
Cyp-mediated (i.e. Cyp1a1) bioactivation of BaP in vivo if very low levels of Por are present, 
but it may also stimulate CYP-mediated metabolic activation of BaP because of its increased 
expression induced by BaP. Therefore, it would be interesting to examine the potential role of 
cytochrome b5 in the metabolic activation of BaP in vivo. Recently, a mouse model has been 
developed, in which cytochrome b5 has been deleted in all tissues [Cytochrome b5 Complete 
Null (BCN)] (McLaughlin et al., 2010), allowing the investigation of general functions of 
cytochrome b5  in carcinogen metabolism in vivo. To dissect the role of hepatic cytochrome b5 
versus hepatic Por in Cyp-mediated bioactivations a conditional liver-specific cytochrome b5 
knockout mouse (Cytb5lox/lox/CreALB; HBN mouse) has been generated (Finn et al., 2008) with 
or without the expression of hepatic Por (Henderson et al., 2013). In the future we plan to 
investigate the balance between Cyp-mediated activation and detoxification of BaP in vivo in 
these potentially improved mouse models. 
As shown in the present study, even low Por expression in livers of HRN mice (Por 
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probably expressed in non-parenchymal cells of liver), in combination with the induction of 
Cyp1a1, cytochrome b5 and mEH by BaP, might be sufficient for an efficient oxidative 
activation of BaP. This feature might follow from a specific pattern of protein levels and 
activities of these enzymes in hepatic microsomes of HRN mice pretreated with BaP that 
resulted in a more than 10- and 34-fold increase in formation of metabolic precursors essential 
for the generation of BaP-DNA adducts; BaP-9-ol as the precursor of 9-hydroxy-BaP-4,5-
epoxide potentially forming adduct 1, and BaP-7,8-dihydrodiol as the precursor of BPDE 
forming the dG-N2-BPDE adduct (adduct 2), respectively. We believe that these findings 
might be one of the potential reasons for the high levels of BaP-DNA adducts formed in livers 
of HRN mice relative to WT mice, but other factors may also contribute. Since it has been 
shown that BaP can increase the activity of some conjugation enzymes (i.e. glutathione S-
transferase) participating in BaP detoxification (Banni et al., 2009), their expression levels 
increased by induction by BaP and contribution to the detoxication of BaP metabolites in the 
HRN model needs further investigation. In addition, the formation and rate of repair of BaP-
DNA adducts and the effect of BaP on the expression of DNA repair proteins may be 
different in HRN and WT mice. Furthermore, the ratio of the hydrophobic DNA adduct 1 to 
dG-N2-BPDE formed by hepatic microsomes and in the CYP1A1-reconstituted systems were 
much higher than the ratios detected in the livers of HRN (compare Fig. 6E) and RCN mice in 
vivo. This might be caused, beside other factors, by differences in the DNA repair of the two 
adducts in vivo or due to efficient conjugation of the BaP-9-ol intermediate.  
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Table 1  
1H chemical shifts of BaP and its metabolites M1, M4, M5 and M7 in hexadeuterated acetone. 
Coupling constants are in parenthesis. 
 
 BaP M1 M4 M5 M7 
H-1 8.33 d (7.8) 
8.26a d 
(7.6) - 
8.02 d 
(9.7) 
8.20 d 
(8.5) 
H-2 8.04 t (7.6) 
8.04 t 
(7.6) 
6.74 d 
(9.8) 
6.69 d 
(9.7) 
7.68 d 
(8.4) 
H-3 8.18 d (7.4) 
8.27a d 
(7.6) 
8.03 d 
(9.7) - - 
H-4 8.09 d (9.2) 
8.12b d 
(8.9) 
8.19 d 
(7.4) 
8.83a d 
(7.7) 
8.30 d 
(9.3) 
H-5 8.01 d (9.1) 
8.15b d 
(8.9) 
8.68 d 
(7.4) 
8.71a d 
(7.7) 
8.00 d 
(9.5) 
H-6 8.65 s 8.09 s - - 8.52 s 
H-7 8.37 dm (8.1) 
7.02 d 
(9.5) 
8.41 dm 
(7.7) 
8.41 dm 
(7.9) 
8.32 s 
(8.1) 
H-8 7.83 ddd (8.0, 6.7, 1.2) 
6.38 dd 
(9.6, 5.3) 7.73 m 7.70 m 7.79 m 
H-9 7.88 ddd (8.4, 6.7, 1.4) 
4.50 dd 
(5.2, 1.7) 7.92 m 7.90 m 7.81 m 
H-10 9.18 dm (8.5) 
5.69 m 
 
8.66 dm 
(8.0) 
8.61 dm 
(8.1) 
9.12 d 
(8.3) 
H-11 9.20 d (9.2) 
8.58 d 
(9.2) 
8.60a d 
(7.9) 
8.76 d 
(7.7) 
8.97 d 
(9.1) 
H-12 8.43 d (9.1) 
8.23 d 
(9.3) 
8.92a d 
(7.9) 
8.12 d 
(7.7) 
8.30 d 
(9.3) 
 
a,bChemical shifts with the same letter in one column may be interchanged. 
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Legends to figures 
Fig. 1. Pathways of biotransformation and DNA adduct formation of BaP catalyzed by 
CYP1A1 and mEH. The two-step activation process by CYP1A1 leading to the 
formation of the ultimately reactive species, 9-hydroxy-BaP-4,5-epoxide, that can 
react with deoxyguanosine in DNA (adduct 1) is shown on the left. The typical three-
step activation process with oxidation by CYP1A1 followed by hydrolysis by mEH 
leads to the ultimately reactive species, BPDE, forming the dG-N2-BPDE adduct 
(adduct 2) is shown on the right.  
Fig. 2.  A, HPLC separation of the BaP metabolites generated by hepatic microsomes of HRN 
mice treated with BaP using Nucleosil C18 reverse phase column. PA, phenacetin, 
M1-M7, BaP metabolites [BaP-9,10-dihydrodiol (M1), BaP-4,5-dihydrodiol (M2), 
BaP-7,8-dihydrodiol (M3), BaP-1,6-dione (M4), BaP-3,6-dione (M5), BaP-9-ol (M6) 
and BaP-3-ol (M7)]. B, Structures of the BaP metabolites. 
Fig. 3.  Relative peak areas of BaP metabolites at 254 nm formed by hepatic microsomes 
isolated from control and BaP-treated HRN mice. Values are averages ± SD of three 
parallel experiments. Comparison was performed by t-test analysis; *P < 0.001, 
different from HRN control microsomes.  
Fig. 4. Relative peak areas of BaP metabolites at 254 nm formed by rat CYP1A1 reconstituted 
with POR. Values are averages ± SD of three parallel experiments.  ND - not 
detected. Comparison was performed by t-test analysis; *P < 0.001, different from 
BaP oxidation by CYP1A1:POR in a ratio of 1:1 than by CYP1A1:POR in a ratio of 
1:0.05. 
Fig. 5. The effect of increasing amounts of cytochrome b5 on oxidation of BaP by A, rat 
CYP1A1 without POR; B, CYP1A1 reconstituted with POR in a ratio of CYP1A1 to 
POR 1:0.05 and C, of 1:1. The values are averages ± SD of relative peak areas of 
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three parallel experiments. Comparison was performed by t-test analysis; *P < 0.001, 
different from BaP oxidation with the CYP1A1/POR system containing cytochrome 
b5 in a ratio of CYP1A1:cytochrome b5 of 1:5 than by that with CYP1A1:cytochrome 
b5 of 1:1 or 1:2.5. 
Fig. 6. Autoradiographic profile of ³²P-labeled DNA adducts generated in calf thymus DNA 
by BaP after its activation with A, CYP1A1 reconstituted with POR (CYP1A1:POR 
of 1:0.2) in the presence of NADPH; B, CYP1A1 reconstituted with POR, mEH and 
cytochrome b5 at ratios of 1:0.2:1:3 in the presence of NADPH; C, the same 
reconstituted system but without NADPH (control incubation); D, hepatic 
microsomes from HRN mice treated with BaP. E, adduct profile of DNA from liver 
of HRN mice treated with BaP.  Analyses were performed by the nuclease P1 version 
of the 32P-postlabeling assay with the TLC conditions described in Materials and 
Methods. Adduct 1 - derived from reaction of 9-hydroxy-BaP-4,5-epoxide with 
deoxyguanosine in DNA; Adduct 2 - dG-N2-BPDE. 
Fig. 7. BaP-DNA adducts formed by CYP1A1 reconstituted with A, POR and B, with POR 
and mEH at a ratio of CYP to mEH of 1:5. RAL - relative adduct labeling. Values are 
averages ± SD of three parallel experiments. Comparison was performed by t-test 
analysis; *P < 0.001, different from BaP-DNA adduct formation by the 
CYP1A1/POR system containing microsomal epoxide hydrolase (mEH) than by that 
without this enzyme. ND - not detected. 
Fig. 8.  The effect of cytochrome b5 on BaP-DNA adduct formation catalyzed by CYP1A1 
reconstituted with POR and mEH at different ratios of the four constituents: A, a 
ratio of CYP1A1 to POR of 1:0.2 with mEH added either without cytochrome b5; B, 
with this protein at a ratio of 1:3 (CYP to cytochrome b5); C, at a CYP1A1 to POR 
ratio of 1:2 with mEH either without cytochrome b5: D, with this protein at a ratio of 
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1:3 (CYP to cytochrome b5). ## - the samples were not analyzed. ND - not detected. 
RAL - relative adduct labeling. Values are averages ± SD of three parallel 
experiments. Comparison was performed by t-test analysis; *P < 0.001, different 
from BaP-DNA adduct formation by the CYP1A1/POR system containing 
cytochrome b5 than by that without this protein. 
Fig. 9. BaP-DNA adducts formed by liver microsomes isolated from control and BaP treated 
HRN mice. RAL - relative adduct labeling. Values are averages ± SD of three 
parallel experiments (Adduct 1 and 2 see Fig. 6). Comparison was performed by t-
test analysis; *P < 0.001, different from HRN control microsomes.  
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